Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adagene Reports Positive Early Results from its anti-CTLA-4 for Colorectal Cancer

publication date: Jan 17, 2024

Suzhou Adagene reported positive early data from a US Phase Ib/II trial of its masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Adagene’s masking technology allows higher, more frequent dosing with better safety, which the company believes will result in a best-in-class candidate. The trial administered ADG126 at a rate of up to 200mg every three weeks in combination with Merck’s anti-PD-1 therapy Keytruda® every three weeks in heavily pretreated patients. The regimen produced a best-in-class safety profile. More details....

Stock Symbol: (NSDQ: ADAG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here